ARTICLE | Company News
Biolex infectious news
May 14, 2012 7:00 AM UTC
Biolex said it is seeking to sell worldwide rights to its remaining asset, hepatitis candidate Locteron. The controlled-release formulation of recombinant interferon (IFN) alpha-2b completed Phase II testing to treat HCV infection. Details were not disclosed (see BioCentury, April 4, 2011). ...